促凋亡基因HtrA2在急性髓系白血病中的表达及临床意义

发布时间：2018-12-11 16:16

【摘要】：目的:研究促凋亡基因HtrA2在急性髓系白血病(AML)中的表达及临床意义。方法:收集78例AML患者(初发组、完全缓解组和难治组)及同期就诊的25例对照组骨髓及外周血标本,提取总RNA,检测HtrA2基因的表达水平,分析不同组别、不同型别之间的HtrA2基因的表达水平。同期随访17例患者。结果:初诊组、完全缓解组和难治组的HtrA2的表达量存在较大的差异,最高值与最低值比值高达68.76,HtrA2水平在不同的患者存在较大差异,3组间差异有统计学意义(χ~2=35.13,P0.05)。FAB各型别间HtrA2基因的相对表达量差异无统计学意义(F=0.004,P0.05)。随诊患者治疗后其HtrA2基因表达明显高于治疗前(P0.05)。HtrA2基因可以影响患者生存时间(Wald=4.979,P0.05),而年龄和性别对患者生存状态的影响无统计学意义(Wald分别为2.426和0.883,P0.05),随访期患者生存曲线分析显示患者的中位生存时间为34.50个月。结论:HtrA2基因的表达水平的检测有助于AML的诊断,治疗及预后评估。
[Abstract]:Objective: to study the expression and clinical significance of apoptotic gene HtrA2 in (AML) of acute myeloid leukemia. Methods: bone marrow and peripheral blood samples were collected from 78 patients with AML (primary group, complete remission group and refractory group) and 25 cases of control group at the same time. Total RNA, was extracted to detect the expression of HtrA2 gene, and different groups were analyzed. The expression level of HtrA2 gene between different types. At the same time, 17 patients were followed up. Results: there was significant difference in the expression of HtrA2 between the newly diagnosed group, the complete remission group and the refractory group. The ratio of the highest value to the lowest value reached 68.76 HtrA2 level in different patients, and there was significant difference among the three groups (蠂 ~ 25.13, P < 0.05). There was no significant difference in the relative expression of HtrA2 gene among all). FAB types (P 0.05). The expression of HtrA2 gene in follow-up patients was significantly higher than that before treatment (P0.05). HtrA2 gene could affect the survival time (Wald=4.979,P0.05) of patients. However, age and sex had no significant effect on survival status (Wald was 2.426 and 0.883%, respectively). The median survival time of patients was 34.50 months. Conclusion: the detection of HtrA2 gene expression is helpful to the diagnosis, treatment and prognosis of AML.
【作者单位】：大连医科大学附属第一医院检验科;大连医科大学;
【分类号】：R733.71;R730.43

【相似文献】